Screener
MiMedx Group MDXG Reportable Segment — Sales & Marketing
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MiMedx Group in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The source filing: MiMedx Group’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001376339-26-000071
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Selling and marketing | $46,416 | $47,867 | $90,328 | $94,728 |
| General and administrative | 13,363 | 16,284 | 22,682 | 29,392 |
| Selling, general and administrative | $59,779 | $64,151 | $113,010 | $124,120 |
Item 1. Financial Statements
FAQ
- What is MiMedx Group's reportable segment — sales & marketing?
- MiMedx Group (MDXG) reported reportable segment — sales & marketing of $46.42M in Q2 2026.
- What does reportable segment — sales & marketing mean?
- This metric represents the total operating expenses specifically allocated to the sales and marketing functions within a reportable business segment. It captures costs associated with advertising, promotional activities, sales force compensation, and market development efforts. Monitoring this spend helps evaluate the efficiency of customer acquisition strategies and the investment intensity required to support revenue growth in specific product lines.
Ask your AI about MiMedx Group's reportable segment — sales & marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude